Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDANCE-06: Targeted Drugs + R-ICE in R/R DLBCL
NCT05348213Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, decitabine, tucidinostat, tofacitinib oral solution, pomalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started May 2022; status: recruiting.
02
Drugs
zanubrutinibdecitabinetucidinostattofacitinib oral solutionpomalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05348213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348213.